Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1853-1856

  van Schie, Rosalin M ^a   Brüggemann, Roger J M ^a   Hoogerbrugge, Peter M ^a   te Loo, D M W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticancer agents; Children; Clinical pharmacology

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BRAIN TOXICITY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONVULSION; DRUG POTENTIATION; DRUG WITHDRAWAL; FUSARIOSIS; HUMAN; NEUROTOXICITY; RATING SCALE; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT DURATION; US NATIONAL CANCER INSTITUTE TOXICITY SCALE; VASOPRESSIN RELEASE;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; AZOLES; CHILD; CHILD, PRESCHOOL; CONSTIPATION; DRUG INTERACTIONS; HUMANS; MYCOSES; PERIPHERAL NERVOUS SYSTEM DISEASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED STATES; VINCRISTINE;

EID: 79960452198     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr223     Document Type: Article

References (10)

1. Gidding CE, Kellie SJ, Kamps WA et al. Vincristine revisited. Crit Rev Oncol Hematol 1999; 29: 267-87.
2. Dennison JB, Kulanthaivel P, Barbuch RJ et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006; 34: 1317-27.
3. Kaya Z, Gursel T, Kocak U et al. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 2009; 52: 470-5.
4. Glasmacher A, Prentice A. Evidence based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005; 56 Suppl 1: 23-32.
5. Rubio PM, Sevilla J, González-Vicent M et al. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade. J Pediatr Hematol Oncol 2009; 31: 642-6.
6. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998; 18: 1304-7.
7. Brüggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
8. Pana ZD, Roilides E. Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer 2011; 57: 30-5.
9. Veerman AJ, Kamps WA, van den Berg H et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-66.
10. Egbelakin A, Ferguson MJ, MacGill EA et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56: 361-7.